BioNTech Q2 2023 Earnings Report $113.08 +1.74 (+1.56%) (As of 05:31 PM ET) Earnings HistoryForecast BioNTech EPS ResultsActual EPS-$0.79Consensus EPS -$0.83Beat/MissBeat by +$0.04One Year Ago EPS$7.31BioNTech Revenue ResultsActual Revenue$167.70 millionExpected Revenue$628.13 millionBeat/MissMissed by -$460.43 millionYoY Revenue Growth-94.80%BioNTech Announcement DetailsQuarterQ2 2023Date8/7/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseBNTX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by What Joe Biden got right (Ad)Anyone with a brain knows Joe Biden failed this country from day one. But, even I must admit there is one thing the Biden administration did right. I call this tech, “The AI Keystone.” It’s the number-one way to capitalize on the trillion-dollar artificial intelligence market.check out my new report. BioNTech Earnings HeadlinesComparing Senti Biosciences (NASDAQ:SNTI) and BioNTech (NASDAQ:BNTX)December 19 at 2:47 AM | americanbankingnews.com3 No-Brainer Biotech Stocks to Buy With $200 Right NowDecember 18 at 5:44 AM | fool.comWhat Joe Biden got rightAnyone with a brain knows Joe Biden failed this country from day one. But, even I must admit there is one thing the Biden administration did right. I call this tech, “The AI Keystone.” It’s the number-one way to capitalize on the trillion-dollar artificial intelligence market.December 20, 2024 | Porter & Company (Ad)J.P. Morgan Reaffirms Their Hold Rating on BioNTech SE (BNTX)December 17 at 11:19 PM | markets.businessinsider.comBioNTech (NASDAQ:BNTX) Research Coverage Started at Wells Fargo & CompanyDecember 14, 2024 | americanbankingnews.comFDA Lifts Hold on BioNTech’s Key Cancer TrialDecember 13, 2024 | tipranks.comSee More BioNTech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioNTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNTech and other key companies, straight to your email. Email Address About BioNTechBioNTech (NASDAQ:BNTX), a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.View BioNTech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
